Warning: Missing argument 1 for get_pagelink_by_slug(), called in /export/sd09/www/jp/r/e/gmoserver/7/3/sd0131973/jpcnma.or.jp/wp-content/themes/jpcnma/header.php on line 111 and defined in /export/sd09/www/jp/r/e/gmoserver/7/3/sd0131973/jpcnma.or.jp/wp-content/themes/jpcnma/admin/functions-theme-basic.php on line 98

機関誌『日中医学』

特集:日中における肺がん最新治療の現状と展望

巻頭言 日中における肺がん最新治療の現状と展望

東京大学医学部附属病院呼吸器外科教授
中島 淳

中国における肺がん治療の現状と展望

中国人民解放軍総医院呼吸器疾患研究所
楊 震※1、陳良安※2
※1 副主任医師 ※2 主任医師、教授(責任著者)

Current status and prospects of the treatment for lung cancer in China

【Abstract】 Lung cancer is the leading cause of cancer-related mortality in global, also in China. In the past decade, much effort was made to improve the survival of lung cancer in China. In this review, we will discuss the current status and prospects of the treatment for lung cancer in China.
【Key words】 China; lung cancer; treatment; survival

中国における肺がん治療の変遷と今後の動向

寧夏医科大学総医院呼吸器・重症医学科教授
張 錦

Lung Cancer Therapy in China: review and perspectives

【Abstract】 Lung cancer is a leading cause of morbidity and mortality among malignant tumors in China. More than 75 % of lung cancers are advanced stage which have little opportunity for doing surgery. Update care of lung cancer include surgery, adjuvant chemotherapy, radiotherapy, molecular targeted therapy, intervention therapy, immunotherapy and Traditional Chinese Medicine treatment. Strategy of lung cancer care is combined the comprehensivel treatmemnt with personalized therapies. The decision making should take consider the desire of patients and their family.
【Key words】 Lung cancer; Surgery; Chemotherapy; Targeted therapy; Immunotherapy

中国の肺がん治療における多科室連携

復旦大学附属中山医院上海市呼吸器疾患研究所所長
白春学

The multidisciplinary collaboration for the treatment of lung cancer in China

【Abstract】 On January 28, 2002, the Chinese first “Lung Cancer Comprehensive Treatment Center” was established in Zhongshan Hospital. On April 26, 2012, “Chinese Alliance against Lung Cancer” was launched focusing on “prevention, early diagnosis and comprehensive treatment of lung cancer.” In five years, consensus or guidelines on lung cancer treatment have been published, including early diagnosis of primary lung cancer, molecularly targeted therapy for advanced non-small cell lung cancer, diagnosis and treatment of pulmonary nodules, treatment of advanced non-small lung cancer with antiangiogenesis drugs. In order to improve the quality of treatment, Medical Internet of things(MIoT)was developed for the management of the patients in community-based hospitals.
【Key words】 Lung cancer; multidisciplinary collaboration; Internet of Things; diagnosis; treatment

日本における肺がん治療の現状と展望

島根大学医学部内科学講座呼吸器・臨床腫瘍学
礒部 威※1、仝雪霞
※1 教授

Overview of the current status of therapeutic strategies for patients with lung cancer in Japan.

【Abstract】 Lung cancer is the most frequent cause of cancer-related deaths in Japan. Recent advances of targeted therapies are substantially changing the management of lung cancers. These treatments include drugs that target driver mutations, those that target presumed important molecules in cancer cell proliferation and survival, and those that inhibit immune checkpoint molecules. This area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. We have also extensively investigated the predictive biomarkers and the molecular mechanisms underlying acquired resistance to these targeted therapies. We review recent progress in the development of targeted treatments for patients with advanced non-small-cell lung cancer.
【Key words】 non-small-cell lung cancer, driver mutation, immune checkpoint inhibitor

日本における肺がん治療の多職種連携

千葉大学大学院医学研究院先端化学療法学教授、
千葉大学医学部附属病院腫瘍内科科長
滝口裕一

Multidisciplinary team for the treatment of patients with lung cancer in Japan

【Abstract】 Recent advancements in drug therapy for lung cancer require comprehensive management of various adverse events arose from various organs. It is achievable with a multidisciplinary team consisting of specifically trained cancer therapy professionals. The team responds to patients’ physical, mental, spiritual and social problems encountered during the course of cancer therapy and palliative care.
【Key words】 Lung cancer; Multidisciplinary team; Toxicity control; Cancer professional; Self-management

随想 Zuiso

癒しの旅
日中医学協会監事、
順天堂大学国際教養学部客員教授
小野喜志雄

日中共同研究こぼれ話 看護共同研究の発展をめざして
東北大学大学院医学系研究科精神看護学分野教授、
河北医科大学第四医院客員教授
吉井初美

インタビュー
~在日中国人研究者を訪ねて~

日本の大学院で学んだ知識と日本の病院勤務での
経験を活かして後進の育成に努めたい
国際医療福祉大学保健医療学部老年看護学准教授
謝海棠
(聞き手・範 江林 広報委員会委員)
架け橋 日中における歯科交流の新潮流
昭和大学名誉教授、
一般社団法人アジアデンタルフォーラム専務理事
岡野友宏 
笹川生 in China サービスはきめ細やかに-日本での受診体験記-
上海市陽子重粒子医院副主任医師
陳 剣
News Letter
~日中医学協会からのお知らせ~
日中医学協会-新役員体制
中国病院薬剤師訪日団の招請
中華医学会訪日団の日中医学協会表敬訪問
笹川医学奨学金進修生同学会(笹川同学会)支部交流会の開催
日中笹川医学奨学金制度第40期研究者募集のお知らせ 
あとがき 髙橋和久  広報委員会委員

『日中医学』特集テーマ「研究報告」一般投稿受付のお知らせ